beta-interferon treatment does not immediately slow the progression of axonal injury in multiple sclerosis

beta-interferon treatment does not immediately slow the progression of axonal injury in multiple sclerosis

Bibliographische Detailangaben
Hauptverfasser:	Parry, A, Corkill, R, Blamire, A, Palace, J, Narayanan, S, Arnold, D, Styles, P, Matthews, P
Format:	Journal article
Veröffentlicht:	2002

Ähnliche Einträge

Beta-Interferon treatment does not always slow the progression of axonal injury in multiple sclerosis.
von: Parry, A, et al.
Veröffentlicht: (2003)

Axonal injury or loss in the internal capsule and motor impairment in multiple sclerosis.
von: Lee, M, et al.
Veröffentlicht: (2000)

Axonal damage in the spinal cord of multiple sclerosis patients detected by magnetic resonance spectroscopy.
von: Blamire, A, et al.
Veröffentlicht: (2007)

Use of Anti-Interferon Beta Antibody Measurements in Multiple Sclerosis
von: Sørensen, P, et al.
Veröffentlicht: (2010)

Axonal loss in the optic nerve and tract in multiple sclerosis
von: Esiri, M, et al.
Veröffentlicht: (2000)

Beta-interferons in multiple sclerosis
von: Aggarwal Sourabh, et al.
Veröffentlicht: (2010-01-01)

Quantitative pathological evidence for axonal loss in normal appearing white matter in multiple sclerosis.
von: Evangelou, N, et al.
Veröffentlicht: (2000)

Evidence for adaptive functional changes in the cerebral cortex with axonal injury from multiple sclerosis.
von: Reddy, H, et al.
Veröffentlicht: (2000)

Interferon beta treatment of multiple sclerosis.
von: Markovitz, D
Veröffentlicht: (1994)

PHARMACOGENETICS OF INTERFERON BETA IN MULTIPLE SCLEROSIS
von: Mohamed Rayen Ganouni, et al.
Veröffentlicht: (2023-10-01)

INTERFERON-BETA TREATMENT OF MULTIPLE-SCLEROSIS - REPLY
von: Sibley, W, et al.
Veröffentlicht: (1994)

Recombinant interferon beta or glatiramer acetate for delaying conversion of the first demyelinating event to multiple sclerosis.
von: Clerico, M, et al.
Veröffentlicht: (2008)

Recombinant interferon beta or glatiramer acetate for delaying conversion of the first demyelinating event to multiple sclerosis.
von: Clerico, M, et al.
Veröffentlicht: (2008)

Treatment of multiple sclerosis with interferon beta-1 b.
von: Abdul-Ahad, A, et al.
Veröffentlicht: (1997)

Regional axonal loss in the corpus callosum correlates with cerebral white matter lesion volume and distribution in multiple sclerosis.
von: Evangelou, N, et al.
Veröffentlicht: (2000)

THE INFLUENCE OF NEUTRALIZING ANTIBODIES TO INTERFERON-BETA ON PROGRESSION OF MULTIPLE SCLEROSIS
von: V. Yu. Lizhdvoy, et al.
Veröffentlicht: (2016-07-01)

Association between cortical metabolite levels and clinical manifestations of migrainous aura: an MR-spectroscopy study.
von: Schulz, U, et al.
Veröffentlicht: (2007)

Interictal cellular energy reserves in migraineurs with prolonged aura or coma and migrainous stroke: A brain P-31-MR-spectroscopy study
von: Schulz, U, et al.
Veröffentlicht: (2003)

31P-and 1H-NMR spectroscopy: A dose-response-relationship between metabolite levels and severity of aura symptoms
von: Schulz, U, et al.
Veröffentlicht: (2006)

Treatment of multiple sclerosis with interferon beta-1b - Reply
von: Sibley, W, et al.
Veröffentlicht: (1997)

Potentially adaptive functional changes in cognitive processing for patients with multiple sclerosis and their acute modulation by rivastigmine.
von: Parry, A, et al.
Veröffentlicht: (2003)

Discordant white matter N-acetylasparate and diffusion MRI measures suggest that chronic metabolic dysfunction contributes to axonal pathology in multiple sclerosis.
von: Cader, S, et al.
Veröffentlicht: (2007)

Renal thrombotic microangiopathy caused by interferon beta-1a treatment for multiple sclerosis
von: Mahe J, et al.
Veröffentlicht: (2013-08-01)

Interferon-Beta-Induced Headache in Patients with Multiple Sclerosis: Frequency and Characterization
von: Elmazny A, et al.
Veröffentlicht: (2020-03-01)

White matter and lesion T1 relaxation times increase in parallel and correlate with disability in multiple sclerosis.
von: Parry, A, et al.
Veröffentlicht: (2002)

A cost-utility analysis of interferon beta for multiple sclerosis.
von: Parkin, et al.
Veröffentlicht: (1998-01-01)

Thrombotic Microangiopathy in Interferon‐beta‐Treated Multiple Sclerosis Patient
von: Masoud Mohammad Malekzadeh, et al.
Veröffentlicht: (2020-06-01)

Treatment for delaying conversion of the first demyelinating event to multiple sclerosis: a Cochrane review on use of recombinant interferon beta or glatiramer acetate
von: Clerico, M, et al.
Veröffentlicht: (2005)

Recombinant interferon-beta efficacy in preventing conversion of clinically isolated syndromes to clinically defined multiple sclerosis: a Cochrane meta-analysis
von: Clerico, M, et al.
Veröffentlicht: (2006)

Curcumin as an add-on therapy for multiple sclerosis in patients receiving interferon-beta therapy
von: A. D. Kukushkina, et al.
Veröffentlicht: (2024-08-01)

Slowing of axonal regeneration is correlated with increased axonal viscosity during aging
von: Heidemann Steven R, et al.
Veröffentlicht: (2010-10-01)

Sarcoidosis and multiple sclerosis: systemic toxicity associated with the use of interferon-beta therapy
von: C. Carbonelli, et al.
Veröffentlicht: (2015-12-01)

Influence of APOE gene polymorphisms on interferon-beta treatment response in multiple sclerosis
von: A.L. Guerrero, et al.
Veröffentlicht: (2011-01-01)

Drug induced liver injury secondary to interferon-beta (IFN-β) in multiple sclerosis
von: V. Byrnes, et al.
Veröffentlicht: (2006-01-01)

Interferon-beta for relapsing-remitting multiple sclerosis: a systematic review
von: Dian HE, et al.
Veröffentlicht: (2014-09-01)

Influence of Interferon beta treatment on quality of life in multiple sclerosis patients
von: De Caro Maria, et al.
Veröffentlicht: (2006-12-01)

Beta-interferons in multiple sclerosis: A single center experience in India
von: Gupta Salil, et al.
Veröffentlicht: (2010-01-01)

Interferon beta: Medication which started the revolution in the treatment of multiple sclerosis
von: Ivanović Jovana, et al.
Veröffentlicht: (2019-01-01)

Profile of PEGylated interferon beta in the treatment of relapsing-remitting multiple sclerosis
von: Cocco E, et al.
Veröffentlicht: (2015-05-01)

Review of the pharmacoeconomics of early treatment of multiple sclerosis using interferon beta
von: Castrop F, et al.
Veröffentlicht: (2013-09-01)